Cardiac output

EDAN's Focus on Medical Technology Advancement Shines at MEDICA 2023

Retrieved on: 
Tuesday, November 14, 2023

DUSSELDORF, Germany, Nov. 14, 2023 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, showcased its innovative range of new products at MEDICA 2023 in Germany.

Key Points: 
  • DUSSELDORF, Germany, Nov. 14, 2023 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, showcased its innovative range of new products at MEDICA 2023 in Germany.
  • This grand event, anticipated to draw over 81,000 visitors and host 4,500 exhibitors from around the globe, took place from November 13 to 16.
  • By achieving technological breakthroughs, our new products symbolize a blooming era for EDAN, where innovation meets excellence, and we continue to set the bar for cutting-edge medical technology."
  • Visit EDAN in person and get hands-on experience at MEDICA at booth 9A62.

Masimo Receives EU MDR CE Mark for LiDCO® Module for Hemodynamic Monitoring

Retrieved on: 
Monday, October 9, 2023

The LiDCO BIC module is designed to connect to multi-patient monitoring platforms, like the Masimo Root® Patient Monitoring and Connectivity Hub, to provide advanced hemodynamic monitoring.

Key Points: 
  • The LiDCO BIC module is designed to connect to multi-patient monitoring platforms, like the Masimo Root® Patient Monitoring and Connectivity Hub, to provide advanced hemodynamic monitoring.
  • With this solution, clinicians can easily add LiDCO hemodynamic monitoring – with its one-of-a-kind versatile PulseCO® algorithm – to their Root patient monitoring hubs.
  • For the first time, there is now a solution that can enable hemodynamic monitoring alongside other supported parameters without having a dedicated hemodynamic monitoring box.
  • Combining Masimo rainbow® Pulse CO-Oximetry and LiDCO hemodynamic monitoring brings the potential for significant new insights into patient status.

Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

Retrieved on: 
Sunday, October 8, 2023

"SAVM utilizes a novel mechanism of action for treating heart failure, so we designed the REBALANCE-HF early feasibility trial to enable us to identify potential responder groups from a broad range of HFpEF patients.

Key Points: 
  • "SAVM utilizes a novel mechanism of action for treating heart failure, so we designed the REBALANCE-HF early feasibility trial to enable us to identify potential responder groups from a broad range of HFpEF patients.
  • The full treatment arm results confirmed the SAVM procedure was safe with no difference in procedure-related adverse events compared to the sham arm.
  • The improvements SAVM demonstrated in the responder group at 6 months were sustained in patients who have available 12-month data.
  • These data will be foundational to our efforts to bring this therapy to the patients who need it most."

PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

Retrieved on: 
Thursday, September 28, 2023

PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.

Key Points: 
  • PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.
  • The PSCA System was successfully deployed and provided hemodynamic stability immediately following implantation and throughout the implant period.
  • “We are extremely excited to lead the First-in-Human clinical investigation of the PercAssist PSCA System for chronic heart failure patients requiring hemodynamic support,” said Professor Neuzil.
  • This extravascular ventricular assist technology has tremendous potential for providing hemodynamic support for heart failure patients without the need for anticoagulation therapy.

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Thursday, August 31, 2023

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase 2 study for its novel inhaled form of sirolimus, LAM-001, for the treatment of pulmonary arterial hypertension (PAH).

Key Points: 
  • GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase 2 study for its novel inhaled form of sirolimus, LAM-001, for the treatment of pulmonary arterial hypertension (PAH).
  • PAH is a rapidly progressive cardiopulmonary disease that affects an estimated 30,000 patients in the United States with a five-year survival rate of approximately 57%.
  • Systemic toxicities have heretofore precluded the widespread adoption of oral sirolimus in certain promising indications despite strong signals of clinical benefit.
  • PAH represents one such orphan pulmonary disorder,” said Dr. Brigette Roberts, Chief Executive Officer of AI Therapeutics.

MoyoAssist® Extra-VAD, a Promising Solution for Short-to-Medium-Term Ventricular Assist for China NMPA trial, Showcased at 4th Academic Annual Conference of CSBE

Retrieved on: 
Saturday, June 17, 2023

Targeting the urgent need for an advanced solution for short-to-medium-term heart support, magAssist has collaborated with China's Wuhan Union Hospital for MoyoAssist®.

Key Points: 
  • Targeting the urgent need for an advanced solution for short-to-medium-term heart support, magAssist has collaborated with China's Wuhan Union Hospital for MoyoAssist®.
  • Powered by intelligent magnetically levitated technology, the system delivers greater portability, vibration resistance, and hemocompatibility, with its exceptional performance and quality exceeding global standard-bearers.
  • "A magnetically levitated artificial heart is an intricate device that encompasses a highly complex structure and control system.
  • In this way, we strive to accelerate the development of medical technology in China and beyond.," said Dr. Po-Lin Hsu, Founder of magAssist.

Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

Retrieved on: 
Wednesday, June 14, 2023

Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.

Key Points: 
  • Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.
  • Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.
  • Fresenius Kabi produces Vasopressin Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems.
  • To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “ More in America .”
    Please see Important Safety Information below.

Sensydia raises $8M round to advance breakthrough CPS cardiac assessment platform

Retrieved on: 
Tuesday, May 9, 2023

Non-invasive cardiac assessment company Sensydia today announced it has raised approximately $8M in new funding from an expanded syndicate of investors.

Key Points: 
  • Non-invasive cardiac assessment company Sensydia today announced it has raised approximately $8M in new funding from an expanded syndicate of investors.
  • View the full release here: https://www.businesswire.com/news/home/20230509005430/en/
    Sensydia’s Cardiac Performance System (CPS™) is designed for fast, safe, and non-invasive cardiac performance assessment that can be performed almost anywhere, avoiding the need to visit a catheterization lab.
  • Source: Sensydia
    Proceeds of the financing will enable the company to prepare for commercialization of its groundbreaking non-invasive cardiac assessment platform, Cardiac Performance System (CPS™) .
  • “Sensydia’s CPS technology is a game-changing AI application that makes crucial cardiac data both accessible and affordable,” said Victoria Grace, Founder of Colle Capital and Sensydia Board Member.

Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime

Retrieved on: 
Thursday, April 27, 2023

Windtree conducted a study of istaroxime in patients experiencing early cardiogenic shock due to heart failure (the SEISMiC Study) and previously reported the publication of the primary analysis of SEISMiC comparing the combined istaroxime dose groups and placebo.

Key Points: 
  • Windtree conducted a study of istaroxime in patients experiencing early cardiogenic shock due to heart failure (the SEISMiC Study) and previously reported the publication of the primary analysis of SEISMiC comparing the combined istaroxime dose groups and placebo.
  • Today, Windtree announces the publication of “Safety and Efficacy of Istaroxime 1.0 and 1.5 μg/kg/min for Patients with Pre Cardiogenic Shock,” in the Journal of Cardiac Failure.
  • “This analysis of our SEISMiC Phase 2 study in pre-cardiogenic shock has provided valuable dose related information,” said Dr. Steve Simonson, SVP and Chief Medical Officer of Windtree Therapeutics.
  • These findings will guide our future development strategy in cardiogenic shock, including in the extension study to SEISMiC, which focuses on dose optimization and longer infusions.”

DrTalks Presents Heal Your Thyroid & Reverse Hashimoto's Summit to Take Place Virtually on July 18 - 24, 2023.

Retrieved on: 
Thursday, April 27, 2023

CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is excited to announce its upcoming virtual summit, the Heal Your Thyroid & Reverse Hashimoto's Summit , taking place from July 18 - 24, 2023.

Key Points: 
  • CARLSBAD, Calif., April 27, 2023 /PRNewswire/ -- DrTalks is excited to announce its upcoming virtual summit, the Heal Your Thyroid & Reverse Hashimoto's Summit , taking place from July 18 - 24, 2023.
  • The summit is aimed at providing valuable information to empower attendees to get to the root of their Hashimoto's, reverse symptoms, and heal their thyroid.
  • The summit will cover the impact of Hashimoto's symptoms and teach holistic Hashimoto's treatment methods that improve physical and mental health.
  • For more information about the Heal Your Thyroid & Reverse Hashimoto's Summit , please visit https://summits.drtalks.com/reverse-hashimotos-summit/ .